Pomalidomide (CC-4047)

For research use only.

Catalog No.S1567

74 publications

Pomalidomide (CC-4047) Chemical Structure

CAS No. 19171-19-8

Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pomalidomide (CC-4047) has been cited by 74 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
Features A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
Targets
CRBN [5]
()
TNF-α [1]
(PBMCs)
13 nM
In vitro

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NFLwfpFEgXSxdH;4bYNqfHliQYPzZZk> MVGxNEDPxE1? MkewNlQhcA>? MVPwc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ? NIX4XWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPFI4Oyd-Mk[zN|gzPzN:L3G+
J-CD38 MlK3R5l1d3SxeHnjbZR6KEG|c3H5 NUXzXm9zOTBizszN M3HMTFI1KGh? MW\wc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ? M4HsS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{O4Nlc{Lz5{NkOzPFI4OzxxYU6=
R-CD38 NHnifnZEgXSxdH;4bYNqfHliQYPzZZk> MXexNEDPxE1? MXmyOEBp Mnn2dI91\W62bImgZZVodWWwdIOg[Ilz\WO2IHHu[EBqdmSrcnXjeEBOVSClZXzsJItqdGyrbnegZpkhW0GU NHrmW3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPFI4Oyd-Mk[zN|gzPzN:L3G+
BC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHn[mNxOzlvMUK1NEBvVQ>? MV:1JIQ> M1TOV2ROW00EoB?= MXPJR|UxRTFyNzDuUUwhcW6qaXLpeJMh[2WubDDJR|UxRTFyNzDuUUwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BCBL-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe1W3J7OzlvMUK1NEBvVQ>? M4f4e|Uh\A>? MkHuSG1UV8Li NHrETIZKSzVyPUe0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 NVP6R|dSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
JSC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XaU|M6NTF{NUCgcm0> Ml3qOUBl NYW3doZmTE2VT9Mg MYTJR|UxRTN2IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
VG-1 NX7UbZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPoOJY{QS1zMkWwJI5O NFrxWHE2KGR? NHvyW|dFVVORwrC= NYiyZ2dIUUN3ME2xNFEhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M1qwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
UMPEL-1 NFzZdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGflOG8{QS1zMkWwJI5O MUi1JIQ> MXHEUXNQyqB? MnPETWM2OD1|MjDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NWqzT4dMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
UMPEL-3 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPEUnc4OzlvMUK1NEBvVQ>? Ml3KOUBl NHG1W5JFVVORwrC= NGOzNopKSzVyPUGxNUBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NF\iZXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
BC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLFbnpCOzlvMUK1NEBvVQ>? MnHlOUBl MXjEUXNQyqB? Mly3TWM2OD15NESgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BCP-1 NYXhUFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HibFM6NTF{NUCgcm0> NEL5PGw2KGR? NYnxPZVoTE2VT9Mg M1fndmlEPTB;M{m2JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
APK-1 NHnPfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvWRm0{QS1zMkWwJI5O M3jXSlUh\A>? M1\pUGROW00EoB?= MniwTWM2OD1{Mk[gcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
RPMI8226  MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWwMlAyNTVyIN88US=> MX:0PEBp M1\1b2ROW00EoB?= NGPycYFKSzVyPUig{txO NILVS|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
OPM2  MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrvSnhsOC5yMT21NEDPxE1? MXG0PEBp MXTEUXNQyqB? NEHrbmZKSzVyPUGwJO69VQ>? M3TLVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm3PFczLz5{NkC5O|g4OjxxYU6=
RPMI8226  NFftfHFHfW6ldHnvckBCe3OjeR?= NFHTVJgyOCEQvF2= NUHJTmpOPDhiaB?= NF70[ZpFVVORwrC= MVzzeJJmdme2aHXud{BkgXSxcHzhd41q[y2wdXPs[YFzKHOqdYT0cIlv\yCxZjDtWG9TKGGwZDDwMY1VV1JicILveIVqdg>? M4HmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm3PFczLz5{NkC5O|g4OjxxYU6=
OPM2  NVW4fopbTnWwY4Tpc44hSXO|YYm= NVP0[I1FOTBizszN MXO0PEBp NVvTfWNQTE2VT9Mg M3jYfpN1emWwZ4To[Y5{KGO7dH;wcIF{dWmlLX71Z4xm[XJic3j1eJRtcW6pIH;mJI1VV1JiYX7kJJAudVSRUjDwdo91\Wmw NH7HTYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
RPMI8226 NIDCe2FHfW6ldHnvckBCe3OjeR?= MVSwMlEuOTBizszN NH[zdJQ1KGh? MYXEUXNQyqB? NVPPU25DcW6lcnXhd4V{KF[HR1[gcXJPSSCneIDy[ZN{cW:w M1TXelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPVkxLz5{NUC1N|k6ODxxYU6=
SH-SY5Y  NF3oO4ZCeG:ydH;zbZMhSXO|YYm= MmrYNlXDqM7:Zz;tUC=> MkjqNeKhcA>? MU\jZZV{\XNic4TheIl{fGmlYXzsfUB{cWewaX\pZ4FvfCC{ZXT1Z5Rqd25iaX6gZo91cCCFUF[tJIFv\CCFUF[rR20ucW6mdXPl[EBieG:ydH;zbZPDqA>? MmnmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{WyO|YoRjJ2OUe1Nlc3RC:jPh?=
JJN3 M2fTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u1S|AvOS1zMECg{txO MYW3NkBp MVHEUXNQ MV7pcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF5OEO3PEc,OjNzN{izO|g9N2F-
XG-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fhc|AvOS1zMECg{txO NYC0bmM4PzJiaB?= MUPEUXNQ NEf4T2lqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M4W4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUe4N|c5Lz5{M{G3PFM4QDxxYU6=
CD138+  NUPrTGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;C[FAvOS1zMECg{txO MYq3NkBp NV7tOFNVTE2VTx?= M{fxfolvcGmkaYTzJINmdGxiZ4Lve5Rp NX7SfoZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxO|g{PzhpPkKzNVc5Ozd6PD;hQi=>
XG-1 NXyxO|RzTnWwY4Tpc44hSXO|YYm= MYWyM|ExOCEQvF2= NWWzNpE1OjRiaB?= NVfX[JpvTE2VTx?= MYDpcohq[mm2czDDR2w{N02LUD2x{tEhdVKQQTDlfJBz\XO|aX;u NEWwcHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
U266 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMlAyNTFyIN88US=> NUiwNlF2PDkkgJno MVLEUXNQ MlL4bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1rIRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWyNFA5Lz5{MkW1NlAxQDxxYU6=
CRBN60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMlAyNTFyIN88US=> M4DmeFQ56oDLaB?= M17QU2ROW09? NFKyRXpqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NIXGXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW1NlAxQCd-MkK1OVIxODh:L3G+
CRNB75 NUS5V|IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSwMlAyNTFyIN88US=> Mmj4OFjjiImq M1\1U2ROW09? MVvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXfpT3pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVIxODhpPkKyOVUzODB6PD;hQi=>
MM.1S MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1PIUxNjBzLUGwJO69VQ>? NIKxWXM1QOLCiXi= MVHEUXNQ NUX6XppMe2mpbnnmbYNidnSueTDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGG2IHPvcoNmdnS{YYTpc45{KGG|IHzve{BieyByLkCx{txO MoPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
OPM2 M1jKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLVfFJGOC5yMT2xNEDPxE1? M{myPVQ56oDLaB?= M2jmO2ROW09? M33wSJNq\26rZnnjZY51dHliaX7obYJqfHNicILvcIln\XKjdHnvckBifCClb37j[Y51emG2aX;ud{BieyCub4egZZMhOC5yMd88US=> NIfzN3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
MM.1S MnnkSpVv[3Srb36gRZN{[Xl? NXXubWU1OTBizszN M3XwRlczKGh? NFHmfXVFVVOR M4f4VJNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> NEntcG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO4PVMzPyd-MkGzPFk{Ojd:L3G+
H929 M1TGdGZ2dmO2aX;uJGF{e2G7 NX:2b|NGOTBizszN MlHpO|IhcA>? NEXqc2pFVVOR M2fJSpNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN6OUOyO{c,OjF|OEmzNlc9N2F-
OPM2 NFGxbVdHfW6ldHnvckBCe3OjeR?= NI\PR2MyOCEQvF2= MnHIO|IhcA>? MVnEUXNQ M4G0SZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> MoLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
CT26 NIi3[nVHfW6ldHnvckBCe3OjeR?= M2ex[lEwOTBizszN MoT2NlQhcA>? NVXDTmtZemWmdXPld{B1cGViboXtZoVzeyCxZjDsbZZmKGOxbH;ubYV{yqB? MkLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4M{i5O|coRjF7NkO4PVc4RC:jPh?=
T-cells MkjYSpVv[3Srb36gZZN{[Xl? NWPlZlBOOiC2bzCzJIRigXN? NVrHR4RVUW6qaXLpeIlwdiCxZjDJUE0zKHC{b3T1Z5Rqd25iaX6gbJVu[W5iVDDj[YxteyCvZXHzeZJm\CCjZoTldkAzKHSxIEOg[IF6eyCkeTDFUGlUSSxiRVO1NEA:KDBwMEC4JO69VS5? MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNkiwNVkoRjJ|MU[4NFE6RC:jPh?=
DF15 MnLISpVv[3Srb36gZZN{[Xl? M{O5e|QhcHK| NI\3b|BKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB{MjFOwG0v MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
DF15 NVPXWFdNTnWwY4Tpc44h[XO|YYm= NE\ZdZU1KGi{cx?= NXTxOJZRUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHnrZZJweyCmZXfyZYRifGmxbjDpckBpfW2jbjDESlE2KGOnbHzzJIV5eHKnc4Ppcoch\VCOLYTh[4dm\CCra3Hyc5Mh[W[2ZYKgOEBpenNiYomgcJVucW6xbXX0dolkKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMkSg{txONg>? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
DF15 MmrHSpVv[3Srb36gZZN{[Xl? M3m0RVQhcHK| MWnJcoR2[3Srb36gc4YhS1KOND;DVmJPKHWkaYH1bZRqdiCuaXfhd4UudWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDwUG9ENWWSTD30ZYdo\WRiYXnvcI9{KGGodHXyJFQhcHK|IHL5JIx2dWmwZYPj[Y5k\SCkYYPl[EBj\XSjLXfhcIFkfG:|aXThd4Uh\W68eX3lJIZz[WevZX70ZZRqd25iY3;tdIxmdWWwdHH0bY9vKGG|c3H5MEBGSzVyIE2gNE4xOjdizszNMi=> M37Oc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{W4OVA4Lz5{OEO1PFUxPzxxYU6=
NAMALWA MmTRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHPHVlc4OiCqcoO= M2PZZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlHNRWxYSSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMEOg{txONg>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4OECxPUc,OjNzNkiwNVk9N2F-
HeLa M{nLNGZ2dmO2aX;uJIF{e2G7 MV;Jcohq[mm2aX;uJI9nKEmOLUGtZYxxcGFvaX7keYNm\CCQRj3rZZBx[UJiYXP0bZZifGmxbjDpckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHLsc4NscW6pIH;mJJA2OC:yNkWgcpVkdGWjcjD0doFve2yxY3H0bY9vNCCLQ{WwJF0hOS5{NzFOwG0v NILQW4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{i0OVg2OCd-MUe4OFU5PTB:L3G+
DF15 M2DjfmZ2dmO2aX;uJIF{e2G7 MYSwMlAyKHSxIEGgeW0> NEjLSVg2KGi{cx?= NFizNYpKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5yMTD0c{AyKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? M1PG[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
OPM2 NUTaPVVQTnWwY4Tpc44h[XO|YYm= Moj2NE4xOSC2bzCxJJVO NVjpdZlbPSCqcoO= M2LxUWlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCra3Hyc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iT2DNNkBk\WyuczDheEAxNjBzIITvJFEhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NEXIVow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
DF15 MWDGeY5kfGmxbjDhd5NigQ>? MnLoNE4xOSC2bzCxJJVO MWO1JIhzew>? NI\DR4VKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiaXvhdo9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOgZZQhOC5yMTD0c{AyKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NY\yXWJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 MY\GeY5kfGmxbjDhd5NigQ>? NYPmOopqOC5yMTD0c{AyKHWP M4rnVlUhcHK| NYn1bGFZUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHHpc4xweyCmZXfyZYRifGmxbjDpckBpfW2jbjDPVG0zKGOnbHzzJIF1KDBwMEGgeI8hOSC3TTDh[pRmeiB3IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| NWrMTJJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
In vivo

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

Protocol

Kinase Assay:

[1]

- Collapse

Inhibition of TNF-α synthesis:

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
Cell Research:

[4]

- Collapse
  • Cell lines: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • Concentrations: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • Incubation Time: 24 or 48 hours
  • Method:

    For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Disseminated lymphoma-bearing SCID mice
  • Dosages: 0.5 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 273.24
Formula

C13H11N3O4

CAS No. 19171-19-8
Storage powder
in solvent
Synonyms N/A
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03113942 Active not recruiting Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst] High Grade Squamous Intra-epithelial Lesion (HSIL) Kirby Institute June 14 2017 Phase 2
NCT02045017 Active not recruiting Drug: Pomalidomide and Dexamethasone Multiple Myeloma Celgene February 28 2014 Phase 2
NCT01177735 Completed Drug: Pomalidomide Multiple Myeloma University of Arkansas|Celgene October 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • Answer:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • Question 2:

    I would like to know if the pomalidomide is racemic or optically active?

  • Answer:

    Our S1567 Pomalidomide is racemic.

E3 ligase Ligand Inhibitors with Unique Features

Tags: buy Pomalidomide (CC-4047) | Pomalidomide (CC-4047) supplier | purchase Pomalidomide (CC-4047) | Pomalidomide (CC-4047) cost | Pomalidomide (CC-4047) manufacturer | order Pomalidomide (CC-4047) | Pomalidomide (CC-4047) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID